Evidence map›Paper›PMID 41326606›Full record

ArticleNature ecology & evolution2026

Pleiotropic mutational effects on function and stability constrain the antigenic evolution of influenza haemagglutinin.

Timothy C Yu, Caroline Kikawa, Bernadeta Dadonaite, Andrea N Loes, Janet A Englund, Jesse D Bloom

Abstract read
In one paragraph

Article in Nature ecology & evolution, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Learning a viral protein's vocabulary.Nature ecology & evolution · 2026
    Article
  11. Functional and antigenic constraints on the Nipah virus fusion protein.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  12. Interim 2025/26 influenza vaccine effectiveness estimates with immuno-epidemiological considerations for A(H3N2) subclade K protection, Canada, January 2026.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  13. Functional and antigenic constraints on the Nipah virus fusion protein.bioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Timothy C YuDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9972-038X
Caroline KikawaDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Bernadeta DadonaiteDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-0908-6982
Andrea N LoesDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Janet A EnglundSeattle Children's Research Institute, Seattle, WA, USA.
Jesse D BloomDivision of Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA. jbloom@fredhutch.org.ORCID http://orcid.org/0000-0003-1267-3408

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7M
TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
Forecasting influenza evolution on a heterogeneous immune landscapeR01AI165821 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Jesse D Bloom, JOHN HUDDLESTON · 2022 to 2026
$3.0M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
FHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600k
National Science Foundation (NSF) DGE-2140004NCI NIH HHS P30 CA015704NIAID NIH HHS 75N93021C00015NIAID NIH HHS R01 AI165821NIGMS NIH HHS T32 GM007270NIH HHS 75N93021C00015NIH HHS S10 OD020069NIH HHS S10 OD028685U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI165821U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) T32GM007270
6 · The paper itself

Abstract

The evolution of human influenza virus haemagglutinin (HA) involves simultaneous selection to acquire antigenic mutations that escape population immunity while preserving protein function and stability. Epistasis shapes this evolution, as an antigenic mutation that is deleterious in one genetic background may become tolerated in another. However, the extent to which epistasis can alleviate pleiotropic conflicts between immune escape and protein function/stability is unclear. Here we measure how all amino acid mutations in the HA of a recent human H3N2 influenza strain affect its cell entry function, acid stability and neutralization by human serum antibodies. We find that epistasis has entrenched certain mutations so that reverting to the ancestral amino acid identity in earlier strains is no longer tolerated. Epistasis has also enabled the emergence of antigenic mutations that were detrimental to the cell entry function of HA in earlier strains. However, epistasis appears insufficient to overcome the pleiotropic costs of antigenic mutations that impair the stability of HA, explaining why some mutations that strongly escape human antibodies never fix in nature. Our results refine our understanding of the mutational constraints that shape recent H3N2 influenza evolution: epistasis can enable antigenic change, but pleiotropic effects can restrict its trajectory.

Indexed as

Evolution, MolecularGenetic PleiotropyHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H3N2 SubtypeEpistasis, GeneticHumansInfluenza, HumanMutationHemagglutinin Glycoproteins, Influenza Virus

Identifiers

PMID41326606
PMCPMC12758803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.